D. Western Therapeutics Institute, Inc. (FRA:6DW)

Market Cap	26.79M -10.8%
Revenue (ttm)	2.10M -17.8%
Net Income	-3.43M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.4460
Previous Close	0.4400
Day's Range	0.4460 - 0.4460
52-Week Range	0.4360 - 0.8550
Beta	n/a
RSI	43.51
Earnings Date	May 12, 2026

About FRA:6DW

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 19
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6DW

Financial Performance

In 2025, FRA:6DW's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.

Financial numbers in JPY